31
Broeker Michael, Kost Holger: Influenza vaccines containing hemagglutinin and matrix proteins. Novartis Vaccines And Diagnostics & Co Kg, Broeker Michael, Kost Holger, MARSHALL Cameron John, August 2, 2007: WO/2007/085969 (8 worldwide citation)

An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less t ...


32
Rappuoli Rino, O Hagan Derek, Del, Giudice Giuseppe: Influenza vaccines including combinations of particulate adjuvants and immunopotentiators. Novartis Vaccines And Diagnostics, Rappuoli Rino, O Hagan Derek, Del, Giudice Giuseppe, MARSHALL Cameron John, May 10, 2007: WO/2007/052058 (8 worldwide citation)

Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgGl). This response can be shifted towards a THl response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic ...


33
YUSIBOV VIDADI: Influenza vaccines, antigens, compositions, and methods. FRAUNHOFER USA, Phillips Eifion, April 1, 2010: WO/2010/036970 (8 worldwide citation)

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and compositions useful in inducing or enhancing an immune response agains influenza antigens. Provided are recombinant protein antigens, compositions, and methods for ...


34
D Aoust Marc Andre, Couture Manon, Ors Frédéric, Trepanier Sonia, Lavoie Pierre Olivier, Dargis Michèle, Vezina Louis Philippe, Landry Nathalie: Influenza virus-like particles (vlps) comprising hemagglutinin. Medicago, D Aoust Marc Andre, Couture Manon, Ors Frédéric, Trepanier Sonia, Lavoie Pierre Olivier, Dargis Michèle, Vezina Louis Philippe, Landry Nathalie, Sechley Konrad A, January 14, 2010: WO/2010/003225 (8 worldwide citation)

A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA of type A/California/04/09 in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP ...


35
Banzhoff Angelika, Clemens Ralf: Combined influenza vaccines for seasonal and pandemic protection. Novartis, Banzhoff Angelika, Clemens Ralf, Marshall Cameron John, December 17, 2009: WO/2009/150532 (8 worldwide citation)

Current approaches to influenza vaccination focus either on seasonal strains or pandemic strains. Current seasonal vaccines typically include antigens from two influenza A strains (H1N1 and H3N2) and one influenza B strain. Current pandemic vaccines focus on H5N1 influenza A virus strains. It is an ...


36
Uytdehaag Alphonsus Gerardus Cornelis Maria, Pau Maria Grazia, Schouten Govert: Production influenza virus vaccines. Crucell Holland, Uytdehaag Alphonsus Gerardus Cornelis Maria, Pau Maria Grazia, Schouten Govert, HATEBOER Guus, April 26, 2007: WO/2007/045674 (8 worldwide citation)

Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of t he virus, and to form a virus-containing medium, and remov ...


37
Tsai Theodore F, Trusheim Heidi: Making influenza virus vaccines without using eggs. Novartis, Tsai Theodore F, Trusheim Heidi, MARSHALL Cameron John, March 20, 2008: WO/2008/032219 (8 worldwide citation)

Currently, the steps performed prior to release of influenza strains to vaccine manufacturers involve passaging influenza virus through eggs. The invention aims to provide procedures useful in manufacturing influenza vaccines, in which the use of eggs is reduced, and preferably is avoided altogether ...


38
Sabine Neirynck, Willy Min Jou, Walter Fiers: Immunoprotective influenza antigen and its use in vaccination. Vlaams Interuniversitair Instituut Voor Biotechnologie, Husch Blackwell Sanders, June 8, 2010: US07731972 (7 worldwide citation)

The present invention relates to an influenza antigen, comprising a fusion product of at least (1) the extracellular part of a conserved influenza membrane protein (e.g., M2) or a functional equivalent thereof and (2) a presenting carrier. The presenting carrier may be a (poly)peptide or a non-pepti ...


39
Jens Peter Gregersen: Decreasing potential iatrogenic risks associated with influenza vaccines. Amy Hessler, Otis Littlefield, Robert J Gorman, February 21, 2012: US08119337 (7 worldwide citation)

Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realized that the conditions used for influenza virus 5 cult ...


40
D Aoust Marc André, Couture Manon, Ors Frédéric, Trépanier Sonia, Lavoie Pierre Olivier, Dargis Michèle, Vézina Louis Philippe, Landry Nathalie: (vlps) Produced in transgenic plants expressing hemagglutinin. Medicago, D Aoust Marc André, Couture Manon, Ors Frédéric, Trépanier Sonia, Lavoie Pierre Olivier, Dargis Michèle, Vézina Louis Philippe, Landry Nathalie, SECHLEY Konrad A, June 25, 2009: WO/2009/076778 (7 worldwide citation)

A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA pro ...